Our Science
Rallybio partners to acquire validated biology for clinical, regulatory, and commercial success.

Rallybio is a clinical-stage biotechnology company developing therapies for severe and rare diseases with pipeline in complement dysregulation and hematology.
rallybio.comCrawled Nov 11, 2026
Rallybio partners to acquire validated biology for clinical, regulatory, and commercial success.
Complement dysregulation drives ocular inflammation in diseases like age-related macular degeneration.
The complement system regulates innate and adaptive immunity; its dysregulation contributes to disease.
RLYB332 is a long-acting monoclonal anti-matriptase-2 antibody that is designed to inhibit MTSP-2 thereby increasing levels of hepcidin, a key protein regulator of iron in the circulation
Prophylactic Administration of HPA-1a–Specific Antibodies Prevents Fetal/Neonatal Alloimmune Thrombocytopenia in Mice Huiying Zhi,1 Douglas Sheridan,2 Debra K.
Journal publications and scientific presentations on FNAIT (fetal and neonatal alloimmune thrombocytopenia) research and prevention.
Rallybio develops therapies for diseases others have overlooked.
Rallybio is a clinical-stage biotech company focused on developing therapies.
234 Church Street New Haven, CT 06510 (203) 859-3820…
Rallybio’s privacy policy explains how it collects user data on its website.
Rallybio Corporation implements a **one-for-two reverse stock split** of its common stock to support its proposed merger with **Avenzo Therapeutics**. The move follows the May 2026 Merger Agreement among Rallybio, Avenzo, and a Farmington Merger Sub subsidiary. The split aligns with restructuring efforts tied to the pending acquisition deal.
Rallybio Corporation and Avenzo Therapeutics have agreed to merge, forming a new entity under Avenzo Therapeutics. The combined company focuses on advancing next-generation oncology treatments, featuring small molecules and antibody-drug conjugates. The merger includes a $215 million private placement to support development efforts.
Rallybio Corporation merges with Candid Therapeutics, forming a combined entity operating under Candid Therapeutics. The move consolidates a portfolio of T-cell engager therapeutics targeting autoimmune diseases. Both companies specialize in immuno-oncology and autoimmune disorder treatments.
RallyBio reports positive Phase 1 trial results for **RLYB116**, a potential best-in-class therapy targeting **complement-mediated diseases**. The data support further investigation into its efficacy for conditions driven by the immune system’s complement pathway. The company highlights RLYB116’s potential as a differentiated treatment option in this therapeutic area.
Rallybio Corporation implements a **one-for-eight reverse stock split** of its common stock. The move follows stockholder approval at a Special Meeting on January 26, 2026, where an amendment to the company’s Certificate of Incorporation was ratified. The split aims to enhance financial flexibility for future strategic decisions.